Omnicell, Inc. (NASDAQ:OMCL) Receives $50.00 Consensus Price Target from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has received an average rating of “Hold” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $50.00.

OMCL has been the subject of several research analyst reports. Benchmark reiterated a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Barclays increased their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Wells Fargo & Company dropped their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Finally, Bank of America lowered their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th.

Insider Buying and Selling

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.64% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OMCL. GAMMA Investing LLC increased its stake in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. Curi RMB Capital LLC raised its stake in Omnicell by 0.7% during the 3rd quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock valued at $3,872,000 after acquiring an additional 651 shares in the last quarter. KBC Group NV boosted its position in Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after acquiring an additional 778 shares during the period. Ensign Peak Advisors Inc grew its stake in shares of Omnicell by 5.0% in the second quarter. Ensign Peak Advisors Inc now owns 17,786 shares of the company’s stock worth $481,000 after purchasing an additional 850 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Omnicell by 6.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company’s stock valued at $635,000 after purchasing an additional 1,360 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

NASDAQ:OMCL opened at $43.63 on Thursday. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -111.87, a price-to-earnings-growth ratio of 29.73 and a beta of 0.78. Omnicell has a one year low of $25.12 and a one year high of $55.74. The business’s 50-day simple moving average is $44.60 and its 200 day simple moving average is $42.14.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.